Hedge Funds Were Right About These 5 Small-Cap Stocks

2. Radius Health Inc. (NASDAQ:RDUS)

Market Cap (As of August 17): $479.8M

Number of Hedge Fund Holdings: 28

YTD Gains (As of August 17): 45.45%

Headquartered in Boston, Massachusetts, Radius Health Inc. (NASDAQ:RDUS) is an American biopharmaceutical company which specializes in the development and production of a new generation of drug therapies for osteoporosis and women’s health. Hedge funds have been stacking up on shares of Radius Health Inc. (NASDAQ:RDUS), the latest example being Rubric Capital Management. The hedge fund bought 1.68 million shares worth $16.95 million on August 12, now owning more than 10% of the company. This hefty purchase came right after the company’s out-licensed drug Elacestrant, which is aimed at patients with ER+/HER2- advanced or metastatic breast cancer, received priority review status by the FDA.

On August 15, Gurnet Point Capital and Patient Square Capital announced the completion of their acquisition of Radius Health (NASDAQ:RDUS). In the course of the transaction, shareholders were paid a consideration of $10.00 per share in cash, plus one non-transferable contingent value right per share. As per the terms and conditions of the merger agreement, the purchaser entity for Gurnet Point and Patient Square merged with Radius (NASDAQ:RDUS), and as a result, Radius (NASDAQ:RDUS) has become a subsidiary of Gurnet Point and Patient Square. Radius (NASDAQ:RDUS) will soon be delisted from the NASDAQ Global Market.